BCLI vs AGEN vs JPM vs NKTR vs FATE

For growth investors, Agenus Inc.

(AGEN) is the stronger pick with 10. 4% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate Agenus Inc. (AGEN) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Agenus Inc.

is actually cheaper at 3. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 5%, compared to -98. 5% for Brainstorm Cell Therapeutics Inc. (BCLI). Over 10 years, the gap is even starker: JPM returned +481. 2% versus BCLI's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Brainstorm Cell Therapeutics Inc.

(BCLI) is the lower-risk stock at 0. 86β versus Agenus Inc. 's 2. 13β — meaning AGEN is approximately 148% more volatile than BCLI relative to the S&P 500. On balance sheet safety, Fate Therapeutics, Inc. (FATE) carries a lower debt/equity ratio of 38% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agenus Inc.

(AGEN) is pulling ahead at 10. 4% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -150. 7% for Brainstorm Cell Therapeutics Inc.. Over a 3-year CAGR, AGEN leads at 5. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 3. 8x forward P/E versus 14. 6x for JPMorgan Chase & Co. — 10. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FATE: 163. 2% to $5. 50.

In this comparison, JPM (1.

8% yield) pays a dividend. BCLI, AGEN, NKTR, FATE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +481. 2%, AGEN: -96. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BCLI (Healthcare) and AGEN (Healthcare) and JPM (Financial Services) and NKTR (Healthcare) and FATE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BCLI is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; NKTR is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock. JPM pays a dividend while BCLI, AGEN, NKTR, FATE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.